Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash & Equivalents (2018 - 2025)

Neurogene's Cash & Equivalents history spans 6 years, with the latest figure at $103.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.97% year-over-year to $103.8 million; the TTM value through Dec 2025 reached $103.8 million, down 23.97%, while the annual FY2025 figure was $103.8 million, 23.97% down from the prior year.
  • Cash & Equivalents reached $103.8 million in Q4 2025 per NGNE's latest filing, up from $71.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $150.1 million in Q1 2024 to a low of $25.2 million in Q3 2023.
  • Average Cash & Equivalents over 3 years is $84.1 million, with a median of $70.9 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: soared 323.0% in 2024, then plummeted 52.86% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $148.2 million in 2023, then dropped by 7.84% to $136.6 million in 2024, then fell by 23.97% to $103.8 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Cash & Equivalents are $103.8 million (Q4 2025), $71.0 million (Q3 2025), and $58.8 million (Q2 2025).